GNB3 and left ventricular hypertrophy: In conclusion, our results suggest that homozygous T allele carriers of the GNB3 polymorphism who are undergoing RRT, especially men, may benefit from intensive antihypertensive therapy to avoid the rapid manifestation of left ventricular hypertrophy, whereas, for the TT/TT genotypes of the GNAQ promoter polymorphism in dialysis patients, close clinical control and strict lifestyle modification and treatment aimed at reducing the risk of coronary artery stenosis and acute cardiovascular events may be recommended.